Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

Nexavar flunks PhIII adjuvant liver cancer trial

11.03.2014 / Scripintelligence

The companies had hoped to show Nexavar's effectiveness at improving hepatocellular carcinoma patients' recurrence-free survival when used after surgery or ablation had removed detectable signs of the disease. However, the trial, which enrolled more than…

Cover_HCLS_GREECE LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: